Notre actualité
Last week we attended ELRIG UK Drug Discovery meeting in ExCeL London, and it was a great pleasure for us to present our poster about neurotoxicity testing using HCS there. Many interesting posters were displayed Read more…
Are your interested in meaning full images and high content analysis to asses your compounds properties ? Pierre-Jean, our dermocosmetic expert, will be present at Cosmetic 360 (the international trade fair for innovative ideas and Read more…
The 20th International Congress on In Vitro Toxicology (ESTIV2018) is coming and it will be a great occasion for HCS-Pharma to showcase our current co-development, with the institute du thorax of Nantes and the RHU Read more…
Dans le cadre de notre développement et de l’ouverture d’un second laboratoire à Lille, nous recherchons une apprentie ou un apprenti “business developer” pour le développement des marchés cosmétique, nutraceutique et toxicologique pour le laboratoire de Rennes. La personne aura Read more…
The 2018 Nobel Prize in Physiology or Medicine has been awarded to James Allisson and Tasuku Honjo for their research about immunotherapy to treat cancer. This therapeutic strategy is based on immune checkpoint targeting. Immune Read more…
In HCS Pharma we strongly believe that 3D is the right way to improve drugs dicovery processes. It’s why we develop our 3D hydroscaffold matrix BIOMIMESYS® for 3D cell culture and we invest in 3D Read more…
Nous sommes à la recherche d’un stagiaire BTS pour fin 2018, pour notre site HCS Pharma de Loos. La personne recrutée travaillera sur un projet R&D en oncologie (culture cellulaire et imagerie). Le projet R&D Read more…
Our study director Elodie will attend Drug Discovery 2018 – THE ELRIG‘s flagship conference – which will take place in London next week! We are looking forward to presenting our poster about neurotoxicity testing. Don’t hesitate to visit Read more…
We are very happy to be highlighted by our partner Molecular Devices in this article : “HCS Pharma uses ImageXpress Micro Confocal Systems for phenotypic screening of physiologically relevant 3D cell models”. We have made a Read more…
Nos différents produits BIOMIMESYS® sont disponibles depuis le début de cette année et nous attachons beaucoup d’importance aux retours de nos clients, à leurs remarques et à leurs questions. Pour simplifier la communication avec notre Read more…
It is a great pleasure for us to welcome a new member in our scientific advisory board, Dr Samuel Meignan! He will for sure help us to develop relevant models related to oncology therapeutic area. Read more…
I was really pleased to participate in the kick-off meeting for the launch of NanoSTEM project, a European Marie Skłodowska-Curie Innovative Training Network (ITN) project, this summer. NanoSTEM is a multidisciplinary and innovative project including 11 Read more…
“Regulation needs to catch up with innovation.” Henry Paulson – CEO Goldman Sachs A very nice state of art about animal testing and its alternatives can be found in the new article “Animal Testing and its Read more…
Melanoma is a type of skin cancer that develops from cells called melanocytes, is one of the fastest-growing and deadliest cancer in the world. It usually caused by DNA damage resulting from exposure to ultraviolet Read more…
Last week, HCS Pharma had the pleasure to attend to COSM’ING 2018 for their 20th anniversary which took place in the Palais du Grand Large at Saint Malo from the 4th to 6th July ! Read more…
Last week we had the pleasure to attend the first SLAS Europe (Society for Laboratory Automation and Screening) meeting, which took place in the great Brussels Square meeting centre (Belgium) between the 27th and the Read more…
HCS pharma has organized its second scientific advisory board! We were pleased to gather around the table (physically or via a Webex visioconference for those who could not make the trip) David Devos, Roméo Cecchelli, Read more…
We are pleased to announce for our US customers that BIOMIMESYS® Hydroscaffold are available for direct sale at our distributor Iwai North America Inc. Thank you again for your previous orders and for your trust in HCS Read more…
Since the liver is responsible for the selective uptake, metabolism and excretion of xenobiotics, this organ is highly predisposed to drug-induced toxicity: this essential function is the primary reason for the failure of pharmaceuticals during Read more…
We are pleased to announce the launch of our new page dedicated to nutraceuticals! We have developed four assays to confirm the efficacy of nutraceuticals on human and animal cells. Our assays are based on Read more…
Meeting us at SLAS Europe 2018, on Wednesday 27th & Thursday 28th of June on Molecular Device Booth (#401) at the Square Brussels Meeting Centre, Brussels, Belgium.
Thank to our partner Integra Biosciences, we are happy to present you an application note about a straightforward workflow for 3D cell seeding and spheroid formation using HCS Pharma’s BIOMIMESYS® plates in combination with INTEGRA’s VIAFLO 96/384 Read more…
As you should know, the GDPR (General Data Protection Regulation) is now a reality and every companies in Europe has to be “compliant” with it. Of course we’re updating our privacy policy (soon) but, in HCS Read more…